Skip to content
http://lifestyle.lmcordoba.com.ar/
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Allarity Therapeutics, Inc.
Allarity Therapeutics Granted Japanese Patent for Stenoparib DRP® Companion Diagnostic, Further Strengthening Stenoparib Development
September 15, 2026
Allarity Therapeutics Announces Strategic Capital Allocation for Filing of SPAC Registration Statement
September 11, 2026
Allarity Therapeutics Reports Second Quarter 2026 Results and Completion of the Phase 3-Ready Stenoparib Manufacturing Campaign
August 17, 2026
Allarity Therapeutics Announces CLIA Certification, Clearing the Path for Advancing DRP® Testing for FDA Registration
July 7, 2026
Allarity Therapeutics Announces the Grant of Essential U.S. Patent for Its Stenoparib DRP® Companion Diagnostic
June 30, 2026
Allarity Therapeutics to Present Trial-in-Progress Poster on Phase 2 Stenoparib Trial at ESMO Gynaecological Cancers Congress 2026
June 18, 2026
Allarity Therapeutics Reports First Quarter 2026 Results and Continued Stenoparib Development in Multiple Cancers
May 24, 2026
Allarity Therapeutics CEO to Present at Precision Medicine Forum Europe 2026 in Stockholm
May 23, 2026
Allarity Therapeutics Advances Stenoparib Toward Pivotal Development with Phase 3 Manufacturing Campaign
May 22, 2026
Allarity Therapeutics Announces that the Stenoparib DRP® Test Has Received a Notice of Allowance from the US Patent and Trademark Office
May 21, 2026
1
2
Next Page
→